Clinical Trial

Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of \[177Lu\]Lu-DFC413 and safety and imaging properties of \[68Ga\]Ga-NNS309 in patients aged ≥ 18 years with solid tumors
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2025-11-21; most recent amendment 2026-06-16.
Trial Details
NCT Number NCT07261631
Lead Sponsor Novartis Pharmaceuticals
Conditions Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Cancer, HR+/HER2- Ductal and Lobular Breast Cancer, Triple Negative Breast Cancer, Colorectal Cancer, Soft Tissue Sarcoma
Enrollment 180 participants
Start Date 2025-11-24
Primary Completion 2029-05-09 (estimated)
Study Completion 2029-05-09 (estimated)
Updated on ClinicalTrials.gov 2026-06-17